ECG
QNCX icon

EPIQ Capital Group’s Quince Therapeutics QNCX Stock Holding History

EPIQ Capital Group’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$1.54M Sell
4,124
-6
-0.1% -$1.8K 0.4% 30
2024
Q3 		$641K Sell
4,130
-132
-3% -$18.9K 0.18% 40
2024
Q2 		$639K Buy
4,262
+33
+0.8% +$5.96K 0.23% 37
2024
Q1 		$897K Sell
4,229
-122
-3% -$30.3K 0.36% 26
2023
Q4 		$914K Sell
4,351
-282
-6% -$56.5K 0.42% 20
2023
Q3 		$1.04M Sell
4,633
-33
-0.7% -$8.62K 0.54% 19
2023
Q2 		$1.4M Sell
4,666
-126
-3% -$39.2K 0.71% 17
2023
Q1 		$1.5M Sell
4,792
-489
-9% -$95.7K 0.75% 16
2022
Q4 		$673K Sell
5,281
-5,002
-49% -$836K 0.37% 24
2022
Q3 		$2.73M Sell
10,283
-6,095
-37% -$2.32M 1.35% 14
2022
Q2 		$7.27M Sell
16,378
-4,019
-20% -$2.84M 2.85% 10
2022
Q1 		$20M Sell
20,397
-949
-4% -$1.29M 5.47% 8
2021
Q4 		$53.9M Buy
21,346
+1,578
+8% +$9.63M 9.57% 3
2021
Q3 		$362M Buy
19,768
+940
+5% +$14.9M 37.45% 1
2021
Q2 		$200M Buy
18,828
+549
+3% +$4.6M 20.85% 2
2021
Q1 		$132M Buy
18,279
+744
+4% +$5.35M 14.71% 3
2020
Q4 		$97.4M Buy
17,535
+461
+3% +$4.08M 15.42% 2
2020
Q3 		$171M Buy
17,074
+360
+2% +$3.27M 24.43% 2
2020
Q2 		$155M Buy
16,714
+742
+5% +$6.8M 26.08% 2
2020
Q1 		$146M Buy
15,972
+255
+2% +$2.52M 43.1% 1
2019
Q4 		$176M Buy
+15,717
New +$94.8M 43.18% 1

Other funds holding QNCX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

EPIQ Capital Group's QNCX Position: Q4 2024 in Review

EPIQ Capital Group reduced its Quince Therapeutics (QNCX) stake by 0.15% in Q4 2024, selling an estimated $1.8K and leaving 4,124 shares worth $1.54M. The position accounts for 0.4% of the portfolio, ranked #30.

EPIQ Capital Group first reported a position in QNCX in Q4 2019 and has held it in 21 quarters since. The position peaked at $362M in Q3 2021. 33 funds tracked by Wall St. Rank hold QNCX as of Q4 2024.

  • EPIQ Capital Group held 4,124 shares of Quince Therapeutics worth $1.54M as of Q4 2024.
  • EPIQ Capital Group sold 6 Quince Therapeutics shares in Q4 2024, an estimated $1.8K.
  • Quince Therapeutics made up 0.4% of EPIQ Capital Group's portfolio in Q4 2024, its #30 holding.
  • EPIQ Capital Group first reported a position in Quince Therapeutics in Q4 2019 and has held it in 21 quarters since.
  • EPIQ Capital Group's Quince Therapeutics position peaked at $362M in Q3 2021.
  • 33 funds tracked by Wall St. Rank held Quince Therapeutics as of Q4 2024.

Based on EPIQ Capital Group's 13F filing for Q4 2024, filed 7 Feb 2025.